Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

- $15 million development milestone payment to InterMune -

- Roche to lead ITMN-191 program in Phase 2 -

BRISBANE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that InterMune has earned a $15 million development milestone under its development collaboration with Roche for the hepatitis C virus (HCV) NS3 protease inhibitor compound ITMN-191 (referred to as R7227 at Roche), currently in a Phase 1b clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin).

Under the terms of their 2006 collaboration agreement, the clinical program for ITMN-191 is now being transitioned to Roche which, starting in Phase 2, will have primary responsibility for completing the global development and registration program.

Nick Cammack, Ph.D., Global Head of the Virology Disease Biology Area, Roche, said, "Protease inhibition is a crucial aspect of our HCV strategy, which is focused on developing clinically differentiated medicines for patients. Our continued enthusiasm for ITMN-191/R7227 underscores our confidence in InterMune and we now plan to rapidly move the program into Phase 2 development."

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased to have led the preclinical development, conducted three Phase 1 clinical trials and with Roche, optimized the manufacturing of ITMN-191 active pharmaceutical ingredient (API) since the collaboration was announced less than two years ago. We look forward to the continued strong relationship with Roche as we together develop protease inhibitor therapies in combination with current standard of care and with other direct antiviral agents."

<
'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial and ... a new genetic test built upon research from their ... will provide physicians with an objective way to ... are stratified between individuals. With this new test, physicians ... a genetic predisposition that will affect their pain tolerance. ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, ... announced that it has received a Canadian Patent ... Actin-Sequestering Peptides.  This patent includes claims using thymosin ... other actin-sequestering peptides for these purposes.  The patent ... RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
(Date:9/30/2014)... OriginOil Inc. (OTC/QB: OOIL), developer of Electro ... up large quantities of water, announced today that in ... the launch of the company's CLEAN-FRACâ„¢ industrial grade demonstrator ... STW Resources . , Immediately upon startup, the ... and achieved a 99.8% reduction in Turbidity on flowback ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2
... to add new apoA1 measurement and apoB:apoA1 ratio to its, ... ... heart disease, BIRMINGHAM, Ala., Nov. 6 ... its VAP(R),Cholesterol Test in booth No. 2918 at the American Heart ...
... Inc. (Pink,Sheets: SNDY) is pleased to announce that the ... from the St. Mary,s,Hospital in Waterbury, CT. St. Mary,s ... yrs and it has chosen to continue using the,Company,s ... vital role in the history of Greater,Waterbury, providing nearly ...
... Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced today that it ... Global Investment Conference to be held,November 10-12, 2008 at ... of,Access is scheduled to speak on Tuesday, November 11, ... corporate overview and discuss the Company,s,product opportunities., The ...
Cached Biology Technology:Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
(Date:9/29/2014)... Behavioral Brain Research provides novel insight into ... of chronic alcohol exposure that can lead to disruptions ... research indicate that individuals with alcohol use disorders frequently ... people are actively drinking, when they are going through ... disturbances can last for months, or even years, after ...
(Date:9/29/2014)... Pangea was starting to break up and dog-sized dinosaurs were ... phytosaurs and rauisuchids were at the top of the food ... didn,t interact much as the former was king of the ... are changing, thanks largely to the contents of a single ... the German journal Naturwissenschaften , Stephanie Drumheller ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2Tooth buried in bone shows prehistoric predators tangled across land, sea 2
... of Oceanography at UC San Diego have developed a ... algae. As reported in this week,s online edition ... Sciences , Scripps graduate student Emily Trentacoste led the ... growth component in biofuel production. In the quest ...
... In what is anticipated to be a major step ... Cell Foundation (NYSCF) Research Institute is partnering with the ... NYSCF scientists will generate stem cell lines from ... researchers to better understand and potentially treat select rare ...
... Smaller bowl sizes may be the next weapon in the battle ... in the Journal of Pediatrics which found children not ... also eat 52 percent more. , "The quickest way parents ... smaller bowl," comments Brian Wansink, professor of behavioral economics and the ...
Cached Biology News:Scripps oceanography researchers engineer breakthrough for biofuel production 2NYSCF and NIH create cell models of rare and undiagnosed diseases 2NYSCF and NIH create cell models of rare and undiagnosed diseases 3
... designed to stabilize the biomolecules during ... There are neither animal proteins ... a convenient 10 times solution in ... to other traditional lyophilizing additives such ...
... benchtop incubator-shaker, has the smallest footprint of all ... 540 x 680 mm (W x D) does ... 505 x 510mm). Available in 25 mm or ... for shaking applications requiring controlled speed and temperature ...
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Biology Products: